Sarepta’s Elevidys Shipments Continue Despite Deaths, FDA Pressure
The pharmaceutical landscape is often a complex interplay of innovation, patient need, and rigorous regulatory oversight. Few stories exemplify this better than that of Sarepta Therapeutics and its groundbreaking gene therapy, Elevidys (delandistrogene moxeparvovec). Designed to treat Duchenne muscular dystrophy (DMD), a devastating genetic disorder, Elevidys has offered a beacon of hope to families. However,…